BCAL DIAGNOSTICS LIMITED — Investor Relations & Filings

BCAL Diagnostics Limited is focused on the development and commercialization of a non-invasive blood test for the early detection of breast cancer. The company's proprietary diagnostic platform utilizes lipidomics and mass spectrometry to identify specific lipid biomarkers associated with the presence of malignancy. This technology aims to provide a highly accurate, cost-effective, and accessible screening tool that complements or serves as an alternative to traditional mammography. By analyzing changes in the lipid profile of a patient's blood, the test is designed to improve detection rates, particularly in younger women and those with dense breast tissue where conventional imaging may be less effective. The company is dedicated to the clinical validation and global implementation of its screening technology to improve patient outcomes through earlier intervention.